A new review was published in Oncotarget on August 2, 2024, entitled, “Targeting WNT5B and WNT10B in osteosarcoma.”
As noted in the abstract of this paper, WNT signaling regulates osteosarcoma proliferation. There is, however, controversy in the field of osteosarcoma as to whether WNT signaling is pro- or anti-tumorigenic. WNT5B, a β-catenin-independent ligand, and WNT10B, a β-catenin-dependent WNT ligand, are each expressed in osteosarcomas, but they are not expressed in the same tumors.
In this review, researchers Gustavo A. Miranda-Carboni and Susan A. Krum from the University of Tennessee Health Science Center in Memphis, identified key osteoblast differentiation genes (SP7 (osterix), ALPL, BMP4, and PHOSPHO1) through RNA-sequencing of osteosarcoma patient tumors. They found that WNT10B correlated positively with these genes, whereas WNT5B showed an inverse correlation.
“As there is controversy over whether we should use WNT activators or WNT inhibitors to treat osteosarcoma, we hypothesize that it depends on whether the canonical or non-canonical pathways are activated, and this remains to be formally tested,” said the researchers.
More information:
Gustavo A. Miranda-Carboni et al, Targeting WNT5B and WNT10B in osteosarcoma, Oncotarget (2024). DOI: 10.18632/oncotarget.28617
Provided by
Impact Journals LLC
Citation:
The targeting of WNT5B and WNT10B in osteosarcoma (2024, September 4)
retrieved 4 September 2024
from https://medicalxpress.com/news/2024-09-wnt5b-wnt10b-osteosarcoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
